Bisphosphonates and other bone agents for breast cancer

O’Carrigan, Brent; Wong, Matthew; Willson, Melina L; Stockler, Martin R.; Pavlakis, Nick; Goodwin, Annabel

doi:10.1002/14651858.cd003474.pub4

Cited by 201 publications

(173 citation statements)

References 152 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Apart from improvement in QoL, median time to SREs is also delayed. Overall survival remains the same [9].…”

Section: Common Indications Of Aras In Oncologymentioning

confidence: 92%

“…OS and PFS were similar with both agents. Similarly, a Cochrane analysis of three trials on breast cancer; denosumab treated women experienced 22% less SREs compared with bisphosphonate treated women (risk ratio [RR] 0.78, 95% CI 0.72-0.85) [9]. Denosumab is easier and quicker to administer, as it is SC injection.…”

Section: Choosing Between Bisphosphonates Vs Denosumabmentioning

confidence: 99%

See 1 more Smart Citation

Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective

Darling¹

2018

JDMS

View full text Add to dashboard Cite

Medication related osteonecrosis of jaw (MRONJ) is a rare iatrogenic disease. Cancer therapeutics is advancing exponentially and apart from a major emphasis on quality of life (QoL) in metastatic patients, now we are foreseeing increased longevity. This necessitates the rising need of betterment of supportive care modalities and looking into the rare complications of therapy. Bisphosphonates (BPs) and Denosumab, the anti-resorptive agents (ARAs) used commonly by medical oncologists in cancers with bone metastases and less commonly in prevention or treatment of osteoporosis, are implicated in the etiology of MRONJ. Many a times, it goes undetected, underdiagnosed and untreated due to lack of awareness, low index of suspicion and paucity of understanding of this disorder amongst medical oncology fraternity. A high index of suspicion is a cornerstone of timely diagnosis and therapeutic action. A regular collaboration between treating oncologist and dentist is of utmost importance. Review Article

show abstract

“…Apart from improvement in QoL, median time to SREs is also delayed. Overall survival remains the same [9].…”

Section: Common Indications Of Aras In Oncologymentioning

confidence: 92%

Section: Choosing Between Bisphosphonates Vs Denosumabmentioning

confidence: 99%

Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective

Darling¹

2018

JDMS

View full text Add to dashboard Cite

show abstract

“…Based on these data, the Cancer Care Ontario and American Society of Clinical Oncology clinical practice guidelines recommend considering bisphosphonates as adjuvant therapy for postmenopausal women with breast cancer who are candidates for systemic therapy. Both zoledronate and clodronate are recommended over ibandronate given that the 50 mg daily dosing schedule of ibandronate in not available in the US and Canada . Insufficient data is available regarding the adjuvant activity of the oral bisphosphonates alendronate and risedronate.…”

Section: Adjuvant Effect Of Antiresorptive Therapy In Postmenopausal mentioning

confidence: 99%

Antiresorptive agents' bone‐protective and adjuvant effects in postmenopausal women with early breast cancer

Chukir

Liu

Farooki

2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

Potent antiresorptive drugs (bisphosphonate and denosumab) are often used to protect bone health in postmenopausal breast cancer patients. In addition, clinical trials have shown that these drugs increase disease-free survival, though the mechanism of adjuvant benefit is largely unknown. Here we review the bone health and adjuvant data for both classes of antiresorptive drugs and highlight differences in their pharmacology. Inhibition of bone resorption is vitally important to protect against osteoporotic fractures, and may also contribute to adjuvant survival benefits by making the bone microenvironment less amenable to breast cancer metastasis. After a course of therapy, stoppage of bisphosphonates yields a persistent antiresorptive effect, whereas discontinuation of denosumab causes a rebound increase in bone resorption markers and a loss of bone mineral density to baseline levels. Whether the potential adjuvant benefits of denosumab are also rapidly lost after drug discontinuation deserves further investigation. esized to prevent skeletal metastases from developing [7]. A multitude of randomized adjuvant bisphosphonate studies Key ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [49].

show abstract

“…50 Patients with metastatic disease can also be treated with bisphosphonates to help reduce bone pain, pathologic fractures, and other skeletal-related events. 51,52 Monoclonal human antibodies such as denosumab have also been found to be efficacious in reducing skeletal-related events compared with bisphosphonate therapy alone. [52][53][54][55] Because metastases from the kidneys and thyroid are very vascular, preoperative embolization of bone lesions should be considered to help decrease intraoperative bleeding.…”

Section: Metastatic Diseasementioning

confidence: 99%

Metastatic Disease, Myeloma, and Lymphoma Affecting the Hip

et al. 2019

View full text Add to dashboard Cite

The three most common causes for bony lesions in patients over 40 years of age are metastatic disease, multiple myeloma, and lymphoma. Oftentimes, these conditions have a predilection for the hip region. The authors present the incidence, characteristics, and treatment of metastatic disease, multiple myeloma, and lymphoma affecting the hip joint to help clinicians accurately diagnose and manage these conditions. They also present the senior author's technique of cemented long stem hemiarthroplasty for treating these conditions when they affect the proximal femur.

show abstract

Bisphosphonates and other bone agents for breast cancer

Abstract: Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Analysis 3.1. Comparison 3 Breast cancer and bone metastases (BCBM), Outcome 1 SREs: bisphosphonate vs placebo/ observation (including hypercalcaemia

Cited by 201 publications

References 152 publications

Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective

Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective

Antiresorptive agents' bone‐protective and adjuvant effects in postmenopausal women with early breast cancer

Metastatic Disease, Myeloma, and Lymphoma Affecting the Hip

Contact Info

Product

Resources

About